azd-6244 and Severe-Dengue

azd-6244 has been researched along with Severe-Dengue* in 1 studies

Other Studies

1 other study(ies) available for azd-6244 and Severe-Dengue

ArticleYear
The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model.
    Archives of virology, 2020, Volume: 165, Issue:3

    Dengue virus (DENV) is the most common mosquito-borne viral disease. The World Health Organization estimates that 400 million new cases of dengue fever occur every year. Approximately 500,000 individuals develop severe and life-threatening complications from dengue fever, such as dengue shock syndrome (DSS) and dengue hemorrhagic fever (DHF), which cause 22,000 deaths yearly. Currently, there are no specific licensed therapeutics to treat DENV illness. We have previously shown that the MEK/ERK inhibitor U0126 inhibits the replication of the flavivirus yellow fever virus. In this study, we demonstrate that the MEK/ERK inhibitor AZD6244 has potent antiviral efficacy in vitro against DENV-2, DENV-3, and Saint Louis encephalitis virus (SLEV). We also show that it is able to protect AG129 mice from a lethal challenge with DENV-2 (D2S20). The molecule is currently undergoing phase III clinical trials for the treatment of non-small-cell lung cancer. The effect of AZD6244 on the DENV life cycle was attributed to a blockade of morphogenesis. Treatment of AG129 mice twice daily with oral doses of AZD6244 (100 mg/kg/day) prevented the animals from contracting dengue hemorrhagic fever (DHF)-like lethal disease upon intravenous infection with 1 × 10

    Topics: Animals; Antiviral Agents; Benzimidazoles; Cell Line; Cricetinae; Dengue Virus; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Interleukin-1beta; Mice; Severe Dengue; Signal Transduction; Tumor Necrosis Factor-alpha

2020